SER-109

BIOLOGICAL4 trials

Sponsors

Seres Therapeutics, Inc.

Conditions

Clostridioides Difficile InfectionClostridium DifficileClostridium Difficile Infection

Phase 2

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

CompletedNCT02437487

Seres Therapeutics, Inc.Clostridium Difficile

Start: 2015-05-31End: 2016-10-31Updated: 2018-07-26

Phase 3

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

CompletedNCT03183128

Seres Therapeutics, Inc.Clostridium Difficile Infection

Start: 2017-07-10End: 2020-09-29Updated: 2023-04-27

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

CompletedNCT03183141

Seres Therapeutics, Inc.Clostridioides Difficile Infection

Start: 2017-10-23End: 2022-04-29Updated: 2023-04-10

Unknown Phase

Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

Seres Therapeutics, Inc.Clostridioides Difficile Infection

Updated: 2023-06-13

Related Papers

The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.

2026-01-05

Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

Infectious Diseases and Therapy2024-06-283 citations

S176 Health-Related Quality of Life With Fecal Microbiota Spores, Live (Formerly SER-109), an Oral Microbiota Therapeutic for Recurrent Clostridioides Difficile Infection: Exploratory Analysis of ECOSPOR IV

The American Journal of Gastroenterology2023-10-01

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent <i>Clostridioides difficile</i> Infection

JAMA Network Open2023-02-1374 citations

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109

JAMA Network Open2023-01-3026 citations

Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent <i>clostridioides difficile</i> infection: Data from ECOSPOR III, a phase 3 randomized trial.

Journal of Clinical Oncology2022-06-012 citations

SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> Infection

New England Journal of Medicine2022-01-19447 citations

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent <i>Clostridioides difficile</i> Infection

Antimicrobial Stewardship & Healthcare Epidemiology2021-07-012 citations

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial

Clinical Infectious Diseases2020-04-05148 citations